Subtopic Deep Dive
TDP-43 Proteinopathy in ALS-FTD
Research Guide
What is TDP-43 Proteinopathy in ALS-FTD?
TDP-43 proteinopathy in ALS-FTD refers to the pathological aggregation, hyperphosphorylation at S409/410, and nuclear clearance of TDP-43 protein in sporadic and familial amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) cases.
TDP-43 inclusions define over 95% of ALS cases and most FTD with motor neuron disease. Key features include cytoplasmic mislocalization, ubiquitination, and disruption of RNA splicing via cryptic exon repression failure (Ling et al., 2015, 668 citations). Studies link TDP-43 to mitochondrial DNA release and cGAS/STING activation (Yu et al., 2020, 901 citations). Approximately 20 papers in provided lists directly address this pathology.
Why It Matters
TDP-43 pathology serves as a primary therapeutic target in ALS-FTD, present in nearly all sporadic ALS cases. Targeting aggregation could halt neurodegeneration, as shown in iPS neuron models of phase separation defects (Prasad et al., 2019). Yu et al. (2020) identified TDP-43-induced mtDNA release activating neuroinflammation via cGAS/STING, offering immunomodulatory strategies. Ling et al. (2015) revealed TDP-43's role in splicing repression, disrupted in disease, enabling cryptic exon-based diagnostics and therapies.
Key Research Challenges
TDP-43 Aggregation Mechanisms
Hyper-phosphorylated TDP-43 at S409/410 forms ubiquitinated inclusions in all sporadic ALS-FTD cases (Neumann et al., 2009, 590 citations). Liquid-liquid phase separation drives pathological fibrils resistant to clearance. Prasad et al. (2019, 735 citations) detail misfolding pathways but therapeutic disaggregation remains elusive.
Cryptic Exon Splicing Disruption
TDP-43 represses nonconserved cryptic exons essential for neuronal survival, compromised in ALS-FTD (Ling et al., 2015, 668 citations). This leads to truncated proteins causing toxicity. No effective methods restore splicing fidelity in patient models.
Neuroinflammatory Pathways
TDP-43 triggers mitochondrial DNA release through mPTP, activating cGAS/STING and NF-κB cytokines (Yu et al., 2020, 901 citations). Blocking this pathway fails to rescue motor neurons in ALS models. Integrating inflammation with aggregation challenges multi-target therapies.
Essential Papers
State of play in amyotrophic lateral sclerosis genetics
Alan E. Renton, Adriano Chiò, Bryan J. Traynor · 2013 · Nature Neuroscience · 1.5K citations
Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report
Peter T. Nelson, Dennis W. Dickson, John Q. Trojanowski et al. · 2019 · Brain · 1.4K citations
We describe a recently recognized disease entity, limbic-predominant age-related TDP-43 encephalopathy (LATE). LATE neuropathological change (LATE-NC) is defined by a stereotypical TDP-43 proteinop...
Hallmarks of neurodegenerative diseases
David M. Wilson, Mark Cookson, Ludo Van Den Bosch et al. · 2023 · Cell · 1.4K citations
Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration
Nigel J. Cairns, Eileen H. Bigio, Ian R. Mackenzie et al. · 2007 · Acta Neuropathologica · 1.1K citations
Amyotrophic lateral sclerosis
Lokesh Wijesekera, P. Nigel Leigh · 2009 · Orphanet Journal of Rare Diseases · 926 citations
Abstract Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterised by progressive muscular paralysis reflecting degeneration of motor neurones in the primary motor cortex, co...
TDP-43 Triggers Mitochondrial DNA Release via mPTP to Activate cGAS/STING in ALS
Chien‐Hsiung Yu, Sophia Davidson, Cassandra R. Harapas et al. · 2020 · Cell · 901 citations
Cytoplasmic accumulation of TDP-43 is a disease hallmark for many cases of amyotrophic lateral sclerosis (ALS), associated with a neuroinflammatory cytokine profile related to upregulation of nucle...
Molecular Mechanisms of TDP-43 Misfolding and Pathology in Amyotrophic Lateral Sclerosis
A. Aditya Prasad, Vidhya Bharathi, Vishwanath Sivalingam et al. · 2019 · Frontiers in Molecular Neuroscience · 735 citations
TAR DNA binding protein 43 (TDP-43) is a versatile RNA/DNA binding protein involved in RNA-related metabolism. Hyper-phosphorylated and ubiquitinated TDP-43 deposits act as inclusion bodies in the ...
Reading Guide
Foundational Papers
Start with Neumann et al. (2009, 590 citations) for S409/410 phosphorylation as universal TDP-43 marker, then Cairns et al. (2007, 1108 citations) for FTLD nosology, and Renton et al. (2013, 1512 citations) for ALS genetics context.
Recent Advances
Study Ling et al. (2015, 668 citations) for cryptic exons, Yu et al. (2020, 901 citations) for mtDNA-cGAS/STING, and Prasad et al. (2019, 735 citations) for misfolding mechanisms.
Core Methods
Immunohistochemistry for inclusions (Neumann 2009); RNA-seq for cryptic exons (Ling 2015); live-cell imaging of phase separation in iPS neurons (Prasad 2019); mitochondrial assays for mPTP (Yu 2020).
How PapersFlow Helps You Research TDP-43 Proteinopathy in ALS-FTD
Discover & Search
PapersFlow's Research Agent uses searchPapers and citationGraph to map TDP-43 papers from Renton et al. (2013, 1512 citations), revealing clusters around ALS genetics and FTD pathology. exaSearch uncovers iPS neuron studies on phase separation, while findSimilarPapers links Yu et al. (2020) to cGAS/STING analogs.
Analyze & Verify
Analysis Agent employs readPaperContent on Ling et al. (2015) to extract cryptic exon data, then runPythonAnalysis with pandas to quantify splicing defects across ALS datasets. verifyResponse via CoVe cross-checks TDP-43 phosphorylation claims against Neumann et al. (2009), with GRADE scoring evidence strength for S409/410 ubiquity.
Synthesize & Write
Synthesis Agent detects gaps in TDP-43 clearance pathways post-Prasad et al. (2019), flagging contradictions in stress granule dynamics. Writing Agent uses latexEditText, latexSyncCitations for ALS-FTD review manuscripts, and latexCompile to generate figures of aggregation models, with exportMermaid for phase separation diagrams.
Use Cases
"Analyze TDP-43 cryptic exon data from ALS patient RNA-seq datasets"
Research Agent → searchPapers('TDP-43 cryptic exons ALS') → Analysis Agent → readPaperContent(Ling 2015) → runPythonAnalysis(pandas on exon inclusion ratios) → statistical verification of splicing defects output.
"Draft LaTeX review on TDP-43 phosphorylation in sporadic ALS"
Synthesis Agent → gap detection(Neumann 2009 + Prasad 2019) → Writing Agent → latexEditText('S409/410 pathology') → latexSyncCitations → latexCompile → compiled PDF with synced references.
"Find GitHub repos with TDP-43 iPS neuron simulation code"
Research Agent → citationGraph(Yu 2020) → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → list of phase separation simulation scripts.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ TDP-43 papers: searchPapers → citationGraph → DeepScan (7-step verification with CoVe checkpoints) → structured report on aggregation pathways. Theorizer generates hypotheses linking TDP-43 mtDNA release (Yu 2020) to LATE-NC (Nelson 2019). DeepScan analyzes cryptic exon datasets from Ling 2015 with runPythonAnalysis for exon quantification.
Frequently Asked Questions
What defines TDP-43 proteinopathy in ALS-FTD?
Cytoplasmic TDP-43 aggregates with nuclear clearance, hyperphosphorylation at S409/410, and ubiquitination in >95% sporadic ALS and FTLD-U cases (Neumann et al., 2009).
What are main methods studying TDP-43 pathology?
iPS-derived motor neurons model phase separation and stress granules; RNA-seq detects cryptic exons (Ling et al., 2015); immunohistochemistry confirms S409/410 phosphorylation (Neumann et al., 2009).
What are key papers on TDP-43 in ALS-FTD?
Ling et al. (2015, Science, 668 citations) on cryptic exons; Yu et al. (2020, Cell, 901 citations) on cGAS/STING; Neumann et al. (2009) on phosphorylation; Prasad et al. (2019) on misfolding.
What open problems exist in TDP-43 research?
Therapeutic clearance of aggregates; restoring splicing repression; blocking TDP-43-induced neuroinflammation without worsening motor loss.
Research Amyotrophic Lateral Sclerosis Research with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching TDP-43 Proteinopathy in ALS-FTD with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers